Buchanan M R, Dejana E, Gent M, Mustard J F, Hirsch J
J Clin Invest. 1981 Feb;67(2):503-8. doi: 10.1172/JCI110059.
Prostacyclin (PGI2) is a powerful inhibitor of platelet aggregation, but its role in the pathogenesis of arterial thrombosis is uncertain. We have studied the thrombogenic effect of inhibiting PGI2 production by aspirin (ASA) in carotid arteries of rabbits given 0, 3, 10, or 100 mg ASA/kg either 1, 3, 6, or 20 h beforehand. Platelet accumulation onto injured carotid arteries was enhanced with ASA in a dose of 10 mg/kg. A higher dose of ASA (100 mg/kg) had no further effect. The enhanced thrombogenic effect of ASA persisted for at least 20 h and was associated with a decrease in vessel wall PGI2 production. There was a strong inverse correlation (r = 0.55, P less than 0.01) between PGI2 production and platelet accumulation. The findings suggest that the margin of safety in obtaining an antithrombotic effect of ASA and producing a potential thrombotic effect in arteries may not be as large as predicted by studies using cultured endothelial cells or experimentally induced thrombosis in veins.
前列环素(PGI2)是血小板聚集的强效抑制剂,但其在动脉血栓形成发病机制中的作用尚不确定。我们研究了预先1、3、6或20小时给予0、3、10或100mg阿司匹林(ASA)/kg的家兔颈动脉中,抑制PGI2生成的阿司匹林的致血栓形成作用。10mg/kg剂量的ASA可增强血小板在损伤颈动脉上的聚集。更高剂量的ASA(100mg/kg)则无进一步作用。ASA增强的致血栓形成作用持续至少20小时,并与血管壁PGI2生成减少有关。PGI2生成与血小板聚集之间存在强烈的负相关(r = 0.55,P < 0.01)。这些发现表明,在获得ASA抗血栓形成作用与在动脉中产生潜在血栓形成作用之间的安全边际,可能不像使用培养内皮细胞或实验性诱导静脉血栓形成的研究所预测的那么大。